VCYT - Veracyte Inc Stock Price, Fair Value and News

21.35USD+0.72 (+3.49%)Market Closed

Market Summary

USD21.35+0.72

Market Closed

3.49%

VCYT Alerts

1 major insider sales recently.

Big jump in Earnings (Y/Y)
Losses in recent quarter

VCYT Stock Price

View Fullscreen

VCYT RSI Chart

VCYT Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-23.13

Price/Sales (Trailing)

4.2

EV/EBITDA

-30.84

Price/Free Cashflow

59.91

VCYT Price/Sales (Trailing)

VCYT Profitability

Operating Margin

90.39%

EBT Margin

-18.76%

Return on Equity

-6.09%

Return on Assets

-5.68%

Free Cashflow Yield

1.67%

VCYT Fundamentals

VCYT Revenue

Revenue (TTM)

375.5M

Rev. Growth (Yr)

17.5%

Rev. Growth (Qtr)

-1.38%

VCYT Earnings

Earnings (TTM)

-68.2M

Earnings Growth (Yr)

76.96%

Earnings Growth (Qtr)

93.41%

Breaking Down VCYT Revenue

52 Week Range

20.6730.52

(Low)(High)

Last 7 days

2.2%

Last 30 days

-3.7%

Last 90 days

-19.3%

Trailing 12 Months

-12.8%

How does VCYT drawdown profile look like?

VCYT Financial Health

Current Ratio

VCYT Investor Care

Shares Dilution (1Y)

5.57%

Diluted EPS (TTM)

-0.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	375.5M	0	0	0
2023	311.2M	328.6M	343.1M	361.1M
2022	250.6M	268.4M	283.6M	296.5M
2021	123.1M	157.5M	186.7M	219.5M
2020	122.0M	112.5M	112.7M	117.5M
2019	101.5M	108.9M	116.4M	120.4M
2018	75.6M	79.9M	85.9M	92.0M
2017	68.0M	71.7M	70.6M	72.0M
2016	51.8M	54.6M	60.9M	65.1M
2015	41.9M	45.2M	47.7M	49.5M
2014	25.0M	28.6M	32.8M	38.2M
2013	14.5M	17.1M	19.5M	21.9M
2012	4.9M	7.1M	9.4M	11.6M
2011	0	0	0	2.6M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Veracyte Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	eastham karin	acquired	131,900	13.19	10,000	-
Apr 01, 2024	eastham karin	sold	-216,528	21.6528	-10,000	-
Mar 15, 2024	stapley marc	sold (taxes)	-125,988	21.1	-5,971	chief executive officer
Mar 15, 2024	chambers rebecca	acquired	-	-	4,318	chief financial officer
Mar 15, 2024	stapley marc	acquired	-	-	11,780	chief executive officer
Mar 15, 2024	chambers rebecca	sold (taxes)	-46,187	21.1	-2,189	chief financial officer
Mar 06, 2024	wygant jonathan	acquired	-	-	23,942	vp, chief accounting officer
Mar 06, 2024	mcguire annie	acquired	-	-	49,880	svp, general counsel
Mar 06, 2024	febbo phillip g.	acquired	-	-	39,904	chief scientific & med officer
Mar 06, 2024	leite john	acquired	-	-	49,880	chief commercial officer-clia

Which funds bought or sold VCYT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 08, 2024	US BANCORP \DE\	added	13.61	-6,888	74,348	-%
May 08, 2024	GREAT LAKES ADVISORS, LLC	new	-	3,101,890	3,101,890	0.03%
May 08, 2024	Bell Investment Advisors, Inc	unchanged	-	-235	976	-%
May 08, 2024	KBC Group NV	unchanged	-	-11,000	43,000	-%
May 08, 2024	GW&K Investment Management, LLC	reduced	-1.39	-8,007,000	30,926,000	0.27%
May 08, 2024	Russell Investments Group, Ltd.	reduced	-70.43	-1,777,380	555,683	-%
May 08, 2024	PROFUND ADVISORS LLC	added	79.41	329,872	1,070,770	0.04%
May 08, 2024	ProShare Advisors LLC	added	9.72	-53,425	406,459	-%
May 08, 2024	WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	added	0.89	-3,786,980	16,435,000	0.04%
May 08, 2024	STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	added	10.97	-57,399	514,149	-%

Are Funds Buying or Selling VCYT?

Are funds buying VCYT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VCYT

No. of Funds

Unveiling Veracyte Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.75%	7,118,211	SC 13G/A
Feb 12, 2024	artisan partners limited partnership	4.4%	3,217,728	SC 13G/A
Feb 08, 2024	wellington management group llp	9.68%	7,068,435	SC 13G/A
Jan 29, 2024	ark investment management llc	10.48%	7,655,603	SC 13G/A
Jan 24, 2024	blackrock inc.	9.8%	7,161,866	SC 13G/A
Jan 22, 2024	state street corp	4.26%	3,108,639	SC 13G/A
Jun 09, 2023	wellington management group llp	10.01%	7,248,889	SC 13G/A
Feb 10, 2023	artisan partners limited partnership	5.2%	3,761,031	SC 13G/A
Feb 10, 2023	ark investment management llc	11.57%	8	SC 13G/A
Feb 10, 2023	invesco ltd.	0.4%	313,974	SC 13G/A

Recent SEC filings of Veracyte Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 17, 2024	8-K/A	Current Report
Apr 02, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 22, 2024	424B7	Prospectus Filed
Mar 22, 2024	8-K	Current Report

Peers (Alternatives to Veracyte Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	9.93%	-6.23%	-7.88	6.87	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.2B	2.0B	-2.86%	-28.22%	-57.69	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-8.14%	-14.08%	75.54	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-3.24%	-16.29%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	1.09%	107.81%	-9.83	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-22.77%	-53.41%	-12.37	9.85	394.93%	39.61%
AXSM	3.5B	251.0M	1.40%	-8.18%	-11.81	13.94	73.58%	-86.73%
ARWR	3.1B	240.7M	-5.68%	-38.85%	-6.52	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-16.31%	-29.84%	-1.5K	3.09	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	-0.76%	-10.51%	28.42	4.5	60.38%	-34.49%
NVAX	627.6M	996.6M	1.36%	-50.17%	-1.57	0.63	-26.66%	65.49%
CRBP	467.5M	881.7K	16.76%	369.92%	-13.85	481.06	-77.61%	33.36%
INO	260.8M	4.9M	-4.04%	14.81%	-1.93	53.59	-54.97%	51.71%
IBIO	6.4M	2.1M	-14.75%	74.53%	-0.24	2.14	-13.45%	66.37%

Veracyte Inc News

Latest updates

Veracyte Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-1.4%	96,844,000	98,199,000	90,108,000	90,322,000	82,422,000	80,297,000	75,592,000	72,864,000	67,783,000	67,336,000	60,370,000	55,105,000	36,703,000	34,536,000	31,121,000	20,704,000	31,122,000	29,730,000	30,973,000	30,136,000	29,529,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,673,000	9,114,000	8,777,000	8,513,000
Costs and Expenses	-24.1%	101,500,000	133,706,000	121,847,000	98,373,000	92,920,000	85,717,000	85,272,000	83,597,000	83,031,000	79,669,000	77,051,000	62,579,000	82,118,000	42,608,000	35,187,000	31,755,000	43,322,000	37,927,000	32,736,000	33,236,000	31,596,000
S&GA Expenses	-5.9%	23,782,000	25,260,000	24,344,000	25,756,000	26,130,000	24,127,000	25,678,000	24,001,000	23,754,000	22,212,000	21,670,000	19,662,000	16,296,000	13,149,000	10,955,000	10,701,000	17,584,000	14,183,000	13,088,000	13,943,000	12,477,000
R&D Expenses	-14.5%	15,965,000	18,673,000	13,322,000	12,541,000	12,769,000	11,287,000	10,773,000	9,377,000	9,166,000	10,252,000	8,006,000	6,249,000	5,336,000	4,586,000	4,042,000	4,169,000	4,407,000	4,443,000	3,643,000	3,330,000	3,435,000
EBITDA Margin	13.8%	-0.12	-0.14	-0.06	-0.01	-0.01	-0.04	-0.07	-0.09	-0.11	-0.28	-0.34	-0.36	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	9,000	-	-	-	-	-27,000	63,000	-	-76,000	55,000	65,000	55,000	-264,000	58,000	235,000	303,000
Income Taxes	97.9%	-44,000	-2,143,500	-200,000	100,000	-	395,500	-152,000	-100,000	-3,000	-760,000	-1,400,000	-152,000	-3,800,000	-	-	-	-	-	-	-	-
Earnings Before Taxes	93.7%	-1,908,000	-30,472,000	-29,772,000	-8,277,000	-8,091,000	-3,441,000	-8,875,000	-9,647,000	-14,464,000	-11,317,000	-15,479,000	-9,190,000	-45,663,000	-8,044,000	-4,124,000	-11,025,000	-11,716,000	-	-	-	-
EBT Margin	11.6%	-0.19	-0.21	-0.14	-0.09	-0.10	-0.12	-0.16	-0.19	-0.20	-0.37	-0.42	-0.43	-	-	-	-	-	-	-	-	-
Net Income	93.4%	-1,864,000	-28,293,000	-29,618,000	-8,402,000	-8,091,000	-3,844,000	-8,723,000	-9,532,000	-14,461,000	-10,528,000	-14,129,000	-9,038,000	-41,868,000	-8,044,000	-4,124,000	-11,025,000	-11,716,000	-7,458,000	-730,000	-2,494,000	-1,917,000
Net Income Margin	11.9%	-0.18	-0.21	-0.15	-0.09	-0.10	-0.12	-0.15	-0.18	-0.19	-0.34	-0.39	-0.40	-	-	-	-	-	-	-	-	-
Free Cashflow	-185.0%	-11,100,000	13,055,000	11,369,000	13,002,000	-3,165,000	7,872,000	5,312,000	-2,873,000	-11,325,000	7,605,000	-3,205,000	360,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	7.6%	1,200	1,115	1,125	1,161	1,157	1,156	1,126	1,144	1,174	1,188	1,186	1,027	1,025	457	454	257	267	275	260	252	124
Current Assets	1.7%	290	286	271	259	252	249	239	235	238	243	229	371	362	376	370	173	181	188	228	220	91.00
Cash Equivalents	-2.9%	210	216	202	191	178	154	171	154	164	173	165	328	325	350	346	148	154	160	196	193	68.00
Inventory	13.6%	18.00	16.00	16.00	12.00	13.00	14.00	14.00	15.00	12.00	11.00	10.00	7.00	6.00	5.00	4.00	7.00	6.00	7.00	7.00	5.00	4.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	12.00	11.00	9.00	9.00	9.00	9.00	9.00	8.00	8.00	8.00
Goodwill	7.2%	754	703	693	699	700	696	677	690	704	708	714	472	475	3.00	3.00	3.00	3.00	3.00	1.00	1.00	1.00
Liabilities	15.0%	81.00	71.00	71.00	78.00	76.00	81.00	78.00	80.00	88.00	91.00	79.00	56.00	51.00	36.00	31.00	31.00	37.00	36.00	29.00	28.00	40.00
Current Liabilities	-5.2%	58.00	61.00	57.00	58.00	56.00	63.00	58.00	59.00	63.00	64.00	50.00	36.00	33.00	17.00	14.00	13.00	19.00	17.00	17.00	15.00	14.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	13.00
LT Debt, Current	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	13.00
Shareholder's Equity	7.1%	1,119	1,044	1,054	1,083	1,081	1,075	1,048	1,064	1,085	1,097	1,107	971	974	421	423	226	230	239	231	224	84.00
Retained Earnings	-0.4%	-469	-468	-439	-410	-401	-393	-389	-381	-371	-357	-346	-332	-323	-281	-273	-269	-258	-246	-239	-238	-236
Additional Paid-In Capital	5.3%	1,617	1,536	1,528	1,521	1,510	1,500	1,492	1,483	1,477	1,469	1,462	1,304	1,298	703	696	496	489	486	470	463	320
Shares Outstanding	4.3%	76.00	73.00	73.00	73.00	72.00	72.00	72.00	71.00	71.00	68.00	70.00	65.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,700	-	-	-	1,400	-	-	-	2,700	-	-	-	1,300	-	-	-	1,300	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-157.7%	-8,966	15,552	14,171	16,671	-2,172	9,744	7,026	-363	-8,872	8,446	-1,393	1,887	-40,561	2,261	1,752	-8,423	-5,301	1,790	-1,556	-2,455	-1,011
Share Based Compensation	6.7%	8,019	7,512	7,263	10,381	7,985	6,867	7,283	5,939	6,645	6,732	7,868	4,064	3,855	3,641	3,089	3,360	2,905	2,842	2,640	2,566	1,759
Cashflow From Investing	215.3%	2,878	-2,497	-2,802	-3,669	24,080	-26,434	8,807	-9,307	-2,453	385	-165,457	1,473	-575,607	-888	-1,635	-649	-665	-41,100	-226	-658	-749
Cashflow From Financing	-234.0%	-864	645	110	397	1,685	93.00	1,486	-75.00	1,990	173	3,215	1,920	591,012	2,911	197,513	3,390	-219	2,965	4,797	127,919	-8,394

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VCYT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 96,844,000	$ 82,422,000
Operating expenses:
Research and development	15,965,000	12,769,000
Selling and marketing	23,782,000	26,130,000
General and administrative	26,210,000	21,053,000
Impairment of long-lived assets	429,000	1,410,000
Intangible asset amortization	3,653,000	5,329,000
Total operating expenses	101,500,000	92,920,000
Loss from operations	(4,656,000)	(10,498,000)
Other income, net	2,748,000	2,407,000
Loss before income taxes	(1,908,000)	(8,091,000)
Income tax benefit	(44,000)	0
Net loss	$ (1,864,000)	$ (8,091,000)
Net loss per common share, basic (in USD per share)	$ (0.02)	$ (0.11)
Net loss per common share, diluted (in USD per share)	$ (0.02)	$ (0.11)
Shares used to compute net loss per common share, basic (in shares)	74,759,789	72,175,457
Shares used to compute net loss per common share, diluted (in shares)	74,759,789	72,175,457
Testing revenue
Revenue:
Total revenue	$ 90,303,000	$ 72,396,000
Operating expenses:
Cost of revenue	25,979,000	19,648,000
Product revenue
Revenue:
Total revenue	3,537,000	3,892,000
Operating expenses:
Cost of revenue	2,644,000	2,162,000
Biopharmaceutical and other revenue
Revenue:
Total revenue	3,004,000	6,134,000
Operating expenses:
Cost of revenue	$ 2,838,000	$ 4,419,000

VCYT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 209,188	$ 216,454
Accounts receivable	46,665	40,378
Supplies and inventory	18,328	16,128
Prepaid expenses and other current assets	16,237	12,661
Total current assets	290,418	285,621
Property, plant and equipment, net	21,566	20,584
Right-of-use assets, operating leases	11,167	10,277
Intangible assets, net	116,348	88,593
Goodwill	753,853	702,984
Restricted cash	1,082	876
Other assets	5,639	5,971
Total assets	1,200,073	1,114,906
Current liabilities:
Accounts payable	12,152	12,943
Accrued liabilities	30,293	38,427
Current portion of deferred revenue	2,602	2,008
Current portion of acquisition-related contingent consideration	6,934	2,657
Current portion of operating lease liabilities	5,982	5,105
Current portion of other liabilities	89	101
Total current liabilities	58,052	61,241
Deferred tax liabilities	1,340	734
Acquisition-related contingent consideration, net of current portion	13,446	518
Operating lease liabilities, net of current portion	8,058	7,525
Other liabilities	528	786
Total liabilities	81,424	70,804
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 125,000,000 shares authorized, 76,425,272 and 73,264,738 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	76	73
Additional paid-in capital	1,617,465	1,536,168
Accumulated deficit	(469,985)	(468,121)
Accumulated other comprehensive loss	(28,907)	(24,018)
Total stockholders’ equity	1,118,649	1,044,102
Total liabilities and stockholders’ equity	$ 1,200,073	$ 1,114,906

About Veracyte Inc

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

CEO	Mr. Marc A. Stapley
WEBSITE	veracyte.com
INDUSTRY	Biotechnology
EMPLOYEES	787

Veracyte Inc Frequently Asked Questions

What is the ticker symbol for Veracyte Inc? What does VCYT stand for in stocks?

VCYT is the stock ticker symbol of Veracyte Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Veracyte Inc (VCYT)?

As of Thu May 09 2024, market cap of Veracyte Inc is 1.58 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VCYT stock?

You can check VCYT's fair value in chart for subscribers.

What is the fair value of VCYT stock?

You can check VCYT's fair value in chart for subscribers. The fair value of Veracyte Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Veracyte Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VCYT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Veracyte Inc a good stock to buy?

The fair value guage provides a quick view whether VCYT is over valued or under valued. Whether Veracyte Inc is cheap or expensive depends on the assumptions which impact Veracyte Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VCYT.

What is Veracyte Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, VCYT's PE ratio (Price to Earnings) is -23.13 and Price to Sales (PS) ratio is 4.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VCYT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Veracyte Inc's stock?

In the past 10 years, Veracyte Inc has provided 0.05 (multiply by 100 for percentage) rate of return.